Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplastic sensory neuropathy (NESPA).

Conditions

paraneoplastic sensory neuropathy with anti-Hu antibodies

Brief summary

Percentage of patients with clinical improvement on the Overall Neuropathy Limitations Scale (ONLS) at 3 months

Detailed description

Percentage of patients with clinical improvement on the ONLS scale at 3 and 6 months, Percentage of patients with improvement of the ataxic component on the Score of Ataxia scale at 3 and 6 months, Percentage of patients with improvement in neuropathic pain on the Numeric Rating Scale (NRS) at 3 and 6 months, Percentage of patients with functional improvement on the modified Rankin Score (mRS) at 3 and 6 month, Percentage of patients with functional improvement on the Barthel Index (BI) at 3 and 6 months, Percentage of patients alive and without tumour progression at 6 months, Tolerability of treatment will be assessed by the frequency and severity of expected and unexpected adverse events recorded during treatment.

Related papers

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Interventions

DRUGCLAIRYG 50 mg/ml

DRUGsolution pour perfusion

DRUGMESNA EG 100 mg/ml

DRUGsolution injectable pour perfusion

DRUGCYCLOPHOSPHAMIDE SANDOZ 1000 mg

DRUGpoudre pour solution injectable ou pour perfusion

DRUGSOLUMEDROL 1 g

DRUGpoudre et solvant pour solution injectable

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of patients with clinical improvement on the Overall Neuropathy Limitations Scale (ONLS) at 3 months	—

Secondary

Measure	Time frame
Percentage of patients with clinical improvement on the ONLS scale at 3 and 6 months, Percentage of patients with improvement of the ataxic component on the Score of Ataxia scale at 3 and 6 months, Percentage of patients with improvement in neuropathic pain on the Numeric Rating Scale (NRS) at 3 and 6 months, Percentage of patients with functional improvement on the modified Rankin Score (mRS) at 3 and 6 month, Percentage of patients with functional improvement on the Barthel Index (BI) at 3 and 6 months, Percentage of patients alive and without tumour progression at 6 months, Tolerability of treatment will be assessed by the frequency and severity of expected and unexpected adverse events recorded during treatment.	—

Measure

Time frame

Percentage of patients with clinical improvement on the ONLS scale at 3 and 6 months, Percentage of patients with improvement of the ataxic component on the Score of Ataxia scale at 3 and 6 months, Percentage of patients with improvement in neuropathic pain on the Numeric Rating Scale (NRS) at 3 and 6 months, Percentage of patients with functional improvement on the modified Rankin Score (mRS) at 3 and 6 month, Percentage of patients with functional improvement on the Barthel Index (BI) at 3 and 6 months, Percentage of patients alive and without tumour progression at 6 months, Tolerability of treatment will be assessed by the frequency and severity of expected and unexpected adverse events recorded during treatment.

—

Countries

France

Outcome results

None listed